Skip to main content

Market Overview

Juno Therapeutics Lower, To Acquire AbVitro For $78 Million In Cash And Nearly 1.30 Million Shares

Share:

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) were trading lower by more than 4 percent at $34.78 during Monday's trading session.

Juno Therapeutics announced earlier that it has acquired AbVitro, Inc., a private biotechnology company whose technology platform accelerates the development of novel immunotherapies by identifying cancer-specific immune cells from natural immune responses at unprecedented resolution.

Juno Therapeutics noted that the acquisition will provide it with a "leading next-generation single cell sequencing platform that will augment Juno's capabilities to create best-in-class engineered T cells against a broad array of cancer targets."

The company also added that it has reached an agreement with principle with Celgene Corporation (NASDAQ: CELG) to license a subset of the acquired technology and grant Celgene options to certain related potential product rights.

Juno Therapeutics has also agreed to pay $78 million in cash and 1,289,193 shares of its stock to acquire AbVitro.

"High throughput, single cell sequencing will meaningfully accelerate our research process in finding both novel antigen targets and appropriate TCR and CAR T cell binders. We remain highly encouraged by the potential of our engineered T cell technology to impact the lives of cancer patients, and this technology improves our capabilities to extend our platform to a broader array of cancer types including solid tumors," said Hy Levitsky, M.D., Juno's Chief Scientific Officer. "We are highly impressed with the quality of the science at AbVitro, and we are delighted to welcome this world-class team to Juno."

 

Related Articles (CELG + JUNO)

View Comments and Join the Discussion!

Posted-In: AbVitro cancer Cancer Drugs CelgeneM&A News Intraday Update Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com